Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

Fulvestrant degrades the oestrogen receptor. Here, the authors report on a clinical trial using fulvestrant and show that mutations in the oestrogen receptor alpha gene are prevalent in circulating tumour DNA and do not influence the clinical outcome of patients to fulvestrant.

Guardado en:

Detalles Bibliográficos
Autores principales:	Jill M. Spoerke, Steven Gendreau, Kimberly Walter, Jiaheng Qiu, Timothy R. Wilson, Heidi Savage, Junko Aimi, Mika K. Derynck, Meng Chen, Iris T. Chan, Lukas C. Amler, Garret M. Hampton, Stephen Johnston, Ian Krop, Peter Schmid, Mark R. Lackner
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2016
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/3ed6583a52b645a290a897ba20ac7a5f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3ed6583a52b645a290a897ba20ac7a5f
record_format	dspace
spelling	oai:doaj.org-article:3ed6583a52b645a290a897ba20ac7a5f2021-12-02T17:32:52ZHeterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant10.1038/ncomms115792041-1723https://doaj.org/article/3ed6583a52b645a290a897ba20ac7a5f2016-05-01T00:00:00Zhttps://doi.org/10.1038/ncomms11579https://doaj.org/toc/2041-1723Fulvestrant degrades the oestrogen receptor. Here, the authors report on a clinical trial using fulvestrant and show that mutations in the oestrogen receptor alpha gene are prevalent in circulating tumour DNA and do not influence the clinical outcome of patients to fulvestrant.Jill M. SpoerkeSteven GendreauKimberly WalterJiaheng QiuTimothy R. WilsonHeidi SavageJunko AimiMika K. DerynckMeng ChenIris T. ChanLukas C. AmlerGarret M. HamptonStephen JohnstonIan KropPeter SchmidMark R. LacknerNature PortfolioarticleScienceQENNature Communications, Vol 7, Iss 1, Pp 1-10 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Jill M. Spoerke Steven Gendreau Kimberly Walter Jiaheng Qiu Timothy R. Wilson Heidi Savage Junko Aimi Mika K. Derynck Meng Chen Iris T. Chan Lukas C. Amler Garret M. Hampton Stephen Johnston Ian Krop Peter Schmid Mark R. Lackner Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
description	Fulvestrant degrades the oestrogen receptor. Here, the authors report on a clinical trial using fulvestrant and show that mutations in the oestrogen receptor alpha gene are prevalent in circulating tumour DNA and do not influence the clinical outcome of patients to fulvestrant.
format	article
author	Jill M. Spoerke Steven Gendreau Kimberly Walter Jiaheng Qiu Timothy R. Wilson Heidi Savage Junko Aimi Mika K. Derynck Meng Chen Iris T. Chan Lukas C. Amler Garret M. Hampton Stephen Johnston Ian Krop Peter Schmid Mark R. Lackner
author_facet	Jill M. Spoerke Steven Gendreau Kimberly Walter Jiaheng Qiu Timothy R. Wilson Heidi Savage Junko Aimi Mika K. Derynck Meng Chen Iris T. Chan Lukas C. Amler Garret M. Hampton Stephen Johnston Ian Krop Peter Schmid Mark R. Lackner
author_sort	Jill M. Spoerke
title	Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
title_short	Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
title_full	Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
title_fullStr	Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
title_full_unstemmed	Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
title_sort	heterogeneity and clinical significance of esr1 mutations in er-positive metastatic breast cancer patients receiving fulvestrant
publisher	Nature Portfolio
publishDate	2016
url	https://doaj.org/article/3ed6583a52b645a290a897ba20ac7a5f
work_keys_str_mv	AT jillmspoerke heterogeneityandclinicalsignificanceofesr1mutationsinerpositivemetastaticbreastcancerpatientsreceivingfulvestrant AT stevengendreau heterogeneityandclinicalsignificanceofesr1mutationsinerpositivemetastaticbreastcancerpatientsreceivingfulvestrant AT kimberlywalter heterogeneityandclinicalsignificanceofesr1mutationsinerpositivemetastaticbreastcancerpatientsreceivingfulvestrant AT jiahengqiu heterogeneityandclinicalsignificanceofesr1mutationsinerpositivemetastaticbreastcancerpatientsreceivingfulvestrant AT timothyrwilson heterogeneityandclinicalsignificanceofesr1mutationsinerpositivemetastaticbreastcancerpatientsreceivingfulvestrant AT heidisavage heterogeneityandclinicalsignificanceofesr1mutationsinerpositivemetastaticbreastcancerpatientsreceivingfulvestrant AT junkoaimi heterogeneityandclinicalsignificanceofesr1mutationsinerpositivemetastaticbreastcancerpatientsreceivingfulvestrant AT mikakderynck heterogeneityandclinicalsignificanceofesr1mutationsinerpositivemetastaticbreastcancerpatientsreceivingfulvestrant AT mengchen heterogeneityandclinicalsignificanceofesr1mutationsinerpositivemetastaticbreastcancerpatientsreceivingfulvestrant AT iristchan heterogeneityandclinicalsignificanceofesr1mutationsinerpositivemetastaticbreastcancerpatientsreceivingfulvestrant AT lukascamler heterogeneityandclinicalsignificanceofesr1mutationsinerpositivemetastaticbreastcancerpatientsreceivingfulvestrant AT garretmhampton heterogeneityandclinicalsignificanceofesr1mutationsinerpositivemetastaticbreastcancerpatientsreceivingfulvestrant AT stephenjohnston heterogeneityandclinicalsignificanceofesr1mutationsinerpositivemetastaticbreastcancerpatientsreceivingfulvestrant AT iankrop heterogeneityandclinicalsignificanceofesr1mutationsinerpositivemetastaticbreastcancerpatientsreceivingfulvestrant AT peterschmid heterogeneityandclinicalsignificanceofesr1mutationsinerpositivemetastaticbreastcancerpatientsreceivingfulvestrant AT markrlackner heterogeneityandclinicalsignificanceofesr1mutationsinerpositivemetastaticbreastcancerpatientsreceivingfulvestrant
_version_	1718380180278345728

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

Ejemplares similares